TITLE

Role of endogenous nitric oxide in regulating antropyloroduodenal motility in humans

AUTHOR(S)
Kuiken, Sjoerd D.; Tytgat, Guido N.J.; Boeckxstaens, Guy E.E.
PUB. DATE
July 2002
SOURCE
American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1661
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES:Previously we demonstrated the involvement of nitric oxide (NO) in the regulation of interdigestive small intestinal motility in humans. The role of NO in postprandial motility remains to be studied. Therefore, we investigated the effect of the NO synthase inhibitor NG-monomethyl-l-arginine (L-NMMA) on antral, pyloric, and small intestinal postprandial motility in healthy volunteers.METHODS:Ten healthy male volunteers (ages 19–29 yr) underwent stationary antropyloroduodenal manometry recording during administration of a placebo or a high dose of L-NMMA (12 mg/kg within 5 min, followed by a maintenance infusion of 6.7 mg/kg/h i.v.) in a double blind, randomized order. Motility was recorded before and after ingestion of a 300-kcal liquid meal.RESULTS:Two and a half minutes (±0.4 min) after infusion of L-NMMA, rapidly propagated phase III-like activity was observed in the proximal duodenum in every subject. Mean propagation velocity was 26 ± 5 cm/min. The duration of the phase III-like activity increased proximally (9.2 ± 1.6 min) to distally (12 ± 1.5 min), whereas the frequencies of contractions were similar in all manometric channels (10.8 ± 0.3/min). Postprandial duodenal motility was disrupted by phase III-like activity in four of 10 subjects (15–58 min after the meal) during L-NMMA infusion, but not during placebo. Antral or pyloric motility and basal pyloric tone were not significantly altered by L-NMMA, relative to the placebo.CONCLUSIONS:We showed that inhibition of NO biosynthesis triggers the onset of a rapidly propagating phase III and shortens the postprandial period, indicating that NO is involved in the modulation of fasting and postprandial small intestinal motility in humans.
ACCESSION #
7839730

 

Related Articles

  • Nitric oxide synthase inhibition results in immediate postoperative recovery of gastric, small intestinal and colonic motility in awake rats. Meile, T.; Glatzle, J.; Habermann, F. M.; Kreis, M. E.; Zittel, T. T. // International Journal of Colorectal Disease;Mar2006, Vol. 21 Issue 2, p121 

    The article presents information on a study which examined the effects of nitric oxide synthase inhibition on gastric, small intestinal and colonic motility in awake rats. The study analysed the motility index, the contraction amplitude, the area under the contraction amplitude and the...

  • Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Akinleye, Akintunde; Avvaru, Parthu; Furqan, Muhammad; Yongping Song; Delong Liu // Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1 

    Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-third of human tumors. Aberrantly activated PI3K signaling also confers sensitivity and...

  • Selective Neuronal Nitric Oxide Synthase Inhibitors. Erdal, Erik P.; Litzinger, Elizabeth A.; Jiwon Seo; Yaoqiu Zhu; Haitao Ji; Silverman, Richard B. // Current Topics in Medicinal Chemistry;Jul2005, Vol. 5 Issue 7, p603 

    This review includes the non-patent literature up to October 2004 that deals with selective neuronal nitric oxide synthase inhibitors (highest potency is for the neuronal isozyme). Some non-selective inhibitors or selective inducible nitric oxide synthase inhibitors are mentioned if they are...

  • Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors. Tafi, A.; Angeli, L.; Venturini, G.; Travagli, M.; Corelli, F.; Botta, M. // Current Medicinal Chemistry;2006, Vol. 13 Issue 16, p1929 

    Crystallographic structures of wild-type and mutant NOS isoforms complexed with substrate, intermediate, inhibitor, cofactor, and cofactor analogs are currently available. However, because of the high level of amino-acid conservation and the consequent similarity in dimeric quaternary structure...

  • Antagonism of nitrous oxide-induced anxiolytic-like behavior in the mouse light/dark exploration procedure by pharmacologic disruption of endogenous nitric oxide function. Li, Shuang; Ohgami, Yusuke; Dai, Yang; Quock, Raymond M. // Psychopharmacology;2003, Vol. 166 Issue 4, p366 

    Abstract Rationale: Previous studies have shown the anxiolytic-like effects of nitrous oxide (N[sub2]O) to be sensitive to antagonism by non-specific inhibitors of nitric oxide synthase (NOS). Objectives: The present study was conducted to demonstrate further the involvement of nitric oxide (NO)...

  • Ruthenium as an Effective Nitric Oxide Scavenger. Marmion, Celine J.; Cameron, Beth; Mulcahy, Clodagh; Fricker, Simon P. // Current Topics in Medicinal Chemistry;Nov2004, Vol. 4 Issue 15, p1585 

    Whilst nitric oxide (NO) has emerged as one of the most versatile and ubiquitous molecules in the human body with a diverse range of physiological functions, dysfunction in NO biosynthesis or metabolism has led to the pathogenesis of a number of disease states. A variety of therapeutic...

  • Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Laufs, Ulrich // European Journal of Clinical Pharmacology;Mar2003, Vol. 58 Issue 11, p719 

    Endothelial dysfunction is now recognised as an important process in the pathogenesis of atherosclerosis. Nitric oxide (NO) release by the endothelium regulates blood flow, inflammation and platelet aggregation, and consequently its disruption during endothelial dysfunction can decrease plaque...

  • Nitric oxide secretion in human conjunctival fibroblasts is inhibited by alpha linolenic acid. Erdinest, Nir; Shohat, Noam; Moallem, Eli; Yahalom, Claudia; Mechoulam, Hadas; Anteby, Irene; Ovadia, Haim; Solomon, Abraham // Journal of Inflammation;10/25/2015, Vol. 12, p1 

    Purpose: It is known that both human conjunctival fibroblasts (HCF) and corneal epithelial (HCE) cells contribute to the inflammatory process in the ocular surface by releasing inflammatory cytokines. In addition, nitric oxide (NO) has an important role in inflammatory responses in the ocular...

  • NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Kalsi, J. S.; Cellek, P. D.; Ralph, D J. // International Journal of Impotence Research;Apr2004, Vol. 16 Issue 2, p195 

    Phosphodiesterase type 5 (PDE5) inhibitors have reduced efficacy in treating erectile dysfunction (ED) in conditions where there is a lack of endogenous nitric oxide (NO). Therefore, NO-releasing PDE5 inhibitors have been developed. Here we report the effect of such a compound, NCX-911, on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics